In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Risk for adverse outcomes increased with antipsychotic use in dementia
Apr 19, 2024
Risks increased for stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia and acute kidney injury.
Nearly 7 million Americans have Alzheimer’s, and caregivers are stressed
Mar 20, 2024
Nearly 7 million American seniors are living with Alzheimer’s dementia, placing a huge strain on both personal caregivers and the US healthcare system, according to a new Alzheimer’s Association...